Correlation Between \textit{MYCN} Gene Status and MYCN Protein Expression in Neuroblastoma: A Pilot Study To Propose the Use of MYCN Immunohistochemistry in Limited-Resource Areas

Teresa Santiago, MD\textsuperscript{1}; Nidale Tarek, MD\textsuperscript{2}; Fouad Boulos, MD\textsuperscript{2}; Caleb Hayes, MPH, MA\textsuperscript{1}; Sima Jeha, MD\textsuperscript{1}; Susana Raimondi, PhD\textsuperscript{1}; and Carlos Rodriguez-Galindo, MD\textsuperscript{1}

\textbf{PURPOSE} The most significant adverse risk factor for neuroblastoma (NB) is \textit{MYCN} gene amplification, which strongly associates with high-risk disease. Fluorescent in situ hybridization (FISH) is considered the best method to evaluate \textit{MYCN} gene status. However, it requires a laboratory that can perform highly complex testing, specialized personnel, and costly reagents. Herein, we aimed to investigate the feasibility of using immunohistochemistry (IHC) to detect MYCN protein expression in lieu of FISH, a strategy potentially useful in areas with limited resources.

\textbf{METHODS} A pilot cohort of 78 patients with NB, including 34 of Middle Eastern descent (MED) who had a higher prevalence of \textit{MYCN} gene amplification (44.11%) and 44 of North American descent (NAD), nine (20.45%) of whom had \textit{MYCN} amplification, was evaluated with IHC for MYCN protein. Correlations of FISH results and protein expression are presented.

\textbf{RESULTS} A positive correlation between \textit{MYCN} gene amplification and protein expression by IHC was seen in 22 (91.66%) of the 24 \textit{MYCN}-amplified NB cases—14 (93.33%) of 15 patients of MED and eight (88.88%) of nine patients of NAD. Agreement between negative FISH and negative IHC results was noted in 18 (94.73%) patients of MED and 34 (97.14%) patients of NAD. Two cases had weak protein expression but no gene amplification (MED: n = 1; 5.0%; NAD: n = 1; 2.9%).

\textbf{CONCLUSION} An excellent overall correlation between \textit{MYCN} gene status by FISH and MYCN protein expression by IHC was confirmed. MYCN IHC in NB with reflexing to FISH in equivocal cases is potentially useful in a limited-resource setting. Evaluation of effectiveness using a larger cohort and optimization to perform MYCN IHC manually is needed.

\textbf{INTRODUCTION} \textit{MYCN} gene amplification is considered the single most relevant genetic alteration in patients with neuroblastoma (NB) and is associated with advanced-stage disease, high-risk category, and poor prognosis.\textsuperscript{1} The overall incidence of \textit{MYCN} gene amplification in patients with NB is approximately 19%, with recognized variations among different ethnic groups, such as 29% in Native American patients\textsuperscript{2} and 44% in patients of Middle Eastern descent (MED).\textsuperscript{3} The methodology of choice to identify \textit{MYCN} gene amplification is fluorescent in situ hybridization (FISH), which can be performed within a rather short turnaround time. However, the availability of the FISH assay is widely restricted to high-income countries owing to the cost of necessary equipment and reagents, and specialized personnel.

On the basis of current estimates, it is expected that more than 400,000 children are diagnosed with cancer worldwide every year.\textsuperscript{4} NB is considered the second most common pediatric solid neoplasm after the brain tumors, representing approximately 6% to 7% of all the pediatric neoplasms.\textsuperscript{5} Even though the incidence of NB appears to be increased in areas that demonstrate a higher human development index,\textsuperscript{6} approximately 24,000 to 28,000 new NB cases are expected per year globally, and a great proportion of them will occur in areas with limited resources. In this pilot study, we investigated the feasibility of using immunohistochemistry (IHC) assay to determine
MYCN protein expression level in patients with NB. We propose the use of the IHC assay as an alternative, cost-effective solution to further risk classify patients with NB in areas with limited resources where the FISH assay to determine MYCN gene status is not readily available.

METHODS

Case Selection
Study approval was obtained from all participating institutions in compliance with the international regulations for protection of human research subjects. From our pathology file, 78 cases diagnosed as NB between July 2014 and July 2017 were selected. They included 34 patients submitted as consecutive pathology consultations for central review from our Middle East partner institution in Lebanon and 44 consecutive patients who were diagnosed and treated in our hospital. The available clinical data, histopathological features, and patient’s outcome were reviewed.

Fluorescence In Situ Hybridization
All 78 cases were evaluated with FISH assay as part of the pathology review. Laboratory-developed probes targeting the MYCN gene (2p24) and a control PAX3 probe (2q35) were used. The MYCN gene was considered amplified when the signals were equal or exceeded more than 10 copies in a given tumor cell nucleus and surpassed at least three times the number of the control signals. The entire tissue section or cytologic smears from bone marrow (BM) aspirates were examined, and at least 200 tumor cells were evaluated. The percentage of neoplastic cells showing gene amplification was documented. Cases with an equal number of MYCN signals and control signals, or with a difference less than three times the number of the control signals were interpreted as negative for MYCN gene amplification.

IHC Analysis
At least one representative formalin-fixed, paraffin-embedded tissue section from each of the 78 cases was selected for the MYCN IHC assay. In brief, heat-induced epitope retrieval was conducted with a ready-to-use EDTA-based solution with pH of 9.0 (BOND Epitope Retrieval Solution 2; Leica, Newcastle, United Kingdom) and incubated for 20 minutes. Mouse monoclonal antibody anti-MYCN (Clone NCM II; catalog no. 16898100; Abcam, Cambridge, MA) was diluted at a 1:150 ratio with a ready-to-use Tris-buffer–based solution (BOND primary antibody diluent, catalog no. AR9352; Leica). All the staining steps were performed using a fully automated IHC stainer (BOND-MAX; Leica). Before examination by light microscopy, all the slides were counter-stained with hematoxylin. Any degree of nuclear staining (strong or weak) in any quantity (diffuse or focal) was categorized as positive and considered evidence of MYCN protein expression. Conversely, cases with no nuclear positivity were interpreted as negative and therefore scored as no indication of MYCN protein expression. All the IHC staining patterns were correlated with the MYCN FISH results.

RESULTS

Clinical Features, Histologic Findings, and FISH results
The main clinical features of all 78 patients are listed in Table 1. Overall, there was no statistically significant difference regarding sex. The youngest patient was diagnosed at 1 week of age and the oldest patient at 19 years of age (mean age at diagnosis, 37.77 months). Most cases were primarily from the adrenal gland (41.03%), and metastatic disease was identified in 45 patients (stage IV, 57.69%). For some patients, the original diagnosis was based on BM involvement. Outcome information is available for 67 patients (85.89%). Seven patients of MED were not treated at our Middle East partner institution; therefore, no additional information was available (pathology consultation only). Four other patients of MED were lost to follow-up.

Table 1 also lists relevant histopathological characteristics such as tumor histology, mitotic-karyorrhectic index (MKI), International Neuroblastoma Pathology Classification (INPC) category, and MYCN gene status evaluated by FISH. As previously reported by our group, a higher incidence of MYCN gene amplification was noted in the patients of MED
| Characteristic | Patients of MED | Patients of NAD | Entire Cohort |
|---------------|----------------|----------------|--------------|
| **Sex**       |                |                |              |
| Female        | 13 (38.23)     | 23 (52.27)     | 36 (46.15)   |
| Male          | 21 (61.77)     | 21 (47.72)     | 42 (53.85)   |
| **Age range, (mean)** | 1 week to 11 years (32.76 months) | 5 weeks to 19 years (41.63 months) | 1 week to 19 years (37.77 months) |
| **Tumor location** |                |                |              |
| Abdominal     | 5 (14.70)      | 5 (11.36)      | 10 (12.82)   |
| Adrenal       | 12 (35.29)     | 20 (45.45)     | 32 (41.03)   |
| Retroperitoneal| 15 (44.13)     | 5 (11.36)      | 20 (25.64)   |
| Thoracic      | 1 (2.94)       | 12 (27.27)     | 13 (16.67)   |
| Cervical      | 0 (0.00)       | 1 (2.28)       | 1 (1.28)     |
| Pelvic        | 1 (2.94)       | 1 (2.28)       | 2 (2.56)     |
| **Histology** |                |                |              |
| NB, SSP, undifferentiated | 4 (11.77) | 0 (0.00) | 4 (5.12) |
| NB, SSP, poorly differentiated | 24 (70.59) | 29 (65.91) | 53 (67.95) |
| NB, SSP, differentiating | 1 (2.94) | 2 (4.54) | 3 (3.85) |
| GNB, nodular composite | 1 (2.94) | 2 (4.54) | 3 (3.85) |
| GNB, SSR, intermixed | 2 (5.88) | 3 (6.82) | 5 (6.41) |
| NB, NOS | 2 (5.88) | 8 (18.19) | 10 (12.82) |
| **Mitotic-karyorrhectic index** |                |                |              |
| Low           | 14 (41.18)     | 14 (31.82)     | 28 (35.89)   |
| Intermediate  | 3 (8.82)       | 9 (20.46)      | 12 (15.39)   |
| High          | 12 (35.29)     | 10 (22.72)     | 22 (28.21)   |
| Cannot be determined | 5 (14.71) | 11 (25.00) | 16 (20.51) |
| **INPC category** |                |                |              |
| Favorable     | 11 (32.35)     | 14 (31.82)     | 25 (32.05)   |
| Unfavorable   | 19 (55.89)     | 22 (50.00)     | 41 (52.57)   |
| Cannot be determined | 4 (11.76) | 8 (18.18) | 12 (15.38) |
| **MYCN gene status** |                |                |              |
| Amplified     | 15 (44.11)     | 9 (20.45)      | 24 (30.77)   |
| Not amplified | 19 (55.89)     | 35 (79.55)     | 54 (69.23)   |
| **Stage**     |                |                |              |
| 1             | 5 (14.71)      | 5 (11.36)      | 10 (12.82)   |
| 2A            | 0 (0.00)       | 2 (4.54)       | 2 (2.56)     |
| 2B            | 1 (2.94)       | 6 (13.64)      | 7 (8.98)     |
| 3             | 6 (17.65)      | 3 (6.82)       | 9 (11.54)    |
| 4             | 17 (50.00)     | 28 (63.64)     | 45 (57.69)   |
| Not available | 1 (2.94)       | 0 (0.00)       | 1 (1.28)     |
| **Outcome**   |                |                |              |
| Alive         | 19 (55.89)     | 35 (79.55)     | 54 (69.23)   |
| Dead          | 4 (11.76)      | 9 (20.45)      | 13 (16.67)   |
| Not available | 11 (32.35)     | 0 (0.00)       | 11 (14.10)   |

**NOTE.** Data presented as No. (%) unless otherwise indicated.

Abbreviations: GNB, ganglioneuroblastoma; INPC, International Neuroblastoma Pathology Classification; MED, Middle Eastern descent; NAD, North American descent; NB, neuroblastoma; NOS, not otherwise specified; SSP, Schwannian stroma-poor; SSR, Schwannian stroma-rich.
when compared with the NAD group (44.11% vs 20.45%, respectively). Among the 24 MYCN-amplified cases in our cohort (24 of 78), the percentage of neoplastic cells showing evidence of MYCN gene amplification in a given tumor ranged from 18.5% to 100%, with an average of 87.89%.

### IHC Findings of MYCN Protein

The correlation between the IHC and FISH results are listed in Table 2. Overall, MYCN protein expression by IHC was seen in 22 (91.66%) of the 24 MYCN-amplified NB cases. The number of positive cells and the intensity of the nuclear staining were heterogeneous among the cases. Diffuse and strong nuclear staining were observed in some cases, whereas others had limited expression with only a few but unequivocally positive nuclei (Figs 1A-1D).

One patient of MED with MYCN amplification had a discordant result and lacked evidence of protein expression (Fig 1H). In one patient of NAD with stage IV disease and BM involvement by NB at diagnosis, the FISH assay was performed on the BM cytologic smears and interpreted as BM involvement by NB at diagnosis, the FISH assay was performed on the diagnostic BM cytologic smear (and MKI measurement) and included all three discordant cases. Fifteen of 16 cases (20.51%) had both MYCN gene amplification and MYCN protein expression. The low-MKI group had the lowest incidence of MYCN gene amplification (two of 28; 7.14%) and included all three discordant cases. Fifteen of 16 cases (93.75%) in which MKI was not assigned had consistent results between FISH and IHC. As previously mentioned, one MYCN-amplified case in which the FISH assay was performed on the post-therapy BM cytologic smear (and MKI was not scored) did not show any viable residual tumor in the available post-therapy resection specimen. Therefore, the correlation between FISH and IHC could not be established in this case.

### DISCUSSION

More than 20 years ago, FISH was described as an alternative method to detect MYCN gene amplification in NB in place of Southern blot analysis. Subsequently, the presence of MYCN gene amplification was recognized as being associated with an aggressive clinical course in patients with NB and therefore required for the risk classification and treatment selection of these patients. Still, the availability of FISH assay remains generally restricted to developed countries. Many of the NB cases we receive for pathology review from international institutions, including the ones referred from our Middle East partner center in Lebanon, are submitted mostly because they are ineffective and included all three discordant cases. Fifteen of 16 cases (93.75%) in which MKI was not assigned had consistent results between FISH and IHC. As previously mentioned, one MYCN-amplified case in which the FISH assay was performed on the diagnostic BM cytologic smear (and MKI was not scored) did not show any viable residual tumor in the available post-therapy resection specimen. Therefore, the correlation between FISH and IHC could not be established in this case.

### Table 2: Correlation Between MYCN Gene Amplification Status by FISH and MYCN Protein Expression by IHC in Patients With Neuroblastoma

| MYCN Protein Expression by IHC | MYCN Gene Amplification by FISH |
|-------------------------------|--------------------------------|
| Positive*                     | Negative*                      | Total*                      |
| Entire cohort                 |                                |                             |
| Positive                      | 22 of 24 (91.66)               | 2 of 54 (3.70)              | 24 |
| Negative                      | 1 of 24 (4.17)                 | 52 of 54 (96.30)            | 53 |
| Indeterminate†                | 1 of 24 (4.17)                 | 0 of 54 (0.00)              | 1  |
| Total                         | 24 of 24 (100.00)             | 54 of 54 (100.00)           | 78 |
| Patients of MED               |                                |                             |
| Positive                      | 14 of 15 (93.33)               | 1 of 19 (5.26)              | 15 |
| Negative                      | 1 of 15 (6.67)                 | 18 of 19 (94.74)            | 19 |
| Indeterminate†                | 0 of 15 (0.00)                 | 0.00 of 19 (0.00)           | 0  |
| Total                         | 15 of 15 (100.00)             | 19 of 19 (100.00)           | 34 |
| Patients of NAD               |                                |                             |
| Positive                      | 8 of 9 (88.80)                 | 1 of 35 (2.86)              | 9  |
| Negative                      | 0 of 9 (0.00)                  | 34 of 35 (97.14)            | 34 |
| Indeterminate†                | 1 of 9 (11.20)                 | 0 of 35 (0.00)              | 1  |
| Total                         | 9 of 9 (100.00)                | 35 of 35 (100.00)           | 44 |

NOTE. Data are given as no. (%) unless otherwise indicated. Abbreviations: FISH, fluorescent in situ hybridization; IHC, immunohistochemistry; MED, Middle Eastern descent; NAD, North American descent. *Discordant results are marked in bold. †No tumor seen in the IHC stained sections.

Agreement between negative FISH and negative IHC was noted in 52 (96.30%) patients—19 (94.73%) patients of MED and 34 (97.14%) patients of NAD. One MYCN-nonamplified case from each group had weak and diffuse (1+) staining (Figs 1F and 1G). In all the three cases with discordant results, the staining for MYCN IHC was repeated at least two times. The sensitivity and specificity of the MYCN IHC assay was 91.66% (95% CI, 71.52 to 98.54) and 96.29% (95% CI, 86.16 to 99.35), respectively.

**Correlation Between MKI, MYCN Gene Status by FISH and MYCN Protein Expression by IHC**

On the basis of MKI, 22 cases (28.21%) were classified as high MKI, 12 (15.38%) were intermediate MKI, and 28 (35.90%) were low MKI. For 16 cases (20.51%), MKI was not assigned, due to the nature of the sample (BM biopsy or post-therapy specimen) or crushing artifact. Thirteen of 22 (59%) of high-MKI NB had MYCN gene amplification by FISH and concordant MYCN protein nuclear overexpression by IHC. In fact, all 22 high-MKI cases had a discordant result between FISH and IHC (Fig 2). Among the 12 cases graded with intermediate MKI, only one (8.33%) had both MYCN gene amplification and MYCN protein expression. The low-MKI group had the lowest incidence of MYCN gene amplification (two of 28; 7.14%) and included all three discordant cases. Fifteen of 16 cases (93.75%) in which MKI was not assigned had consistent results between FISH and IHC. As previously mentioned, one MYCN-amplified case in which the FISH assay was performed on the post-therapy BM cytologic smear (and MKI was not scored) did not show any viable residual tumor in the available post-therapy resection specimen. Therefore, the correlation between FISH and IHC could not be established in this case.
In fact, the majority of the MYCN-amplified NBs express MYCN protein. However, there is also evidence that overexpression of MYCN protein can happen in cases without gene amplification and similarly appears to act as an independent poor prognostic factor.

In this pilot study, we investigated how well, in our hands, the expression of MYCN protein by IHC would correlate with our FISH results in samples collected and processed in our hospital, as well as in referred specimens from one of our international partner sites. The possibility of using IHC in lieu of the FISH assay in cases of NB seems to be a potentially useful strategy and cost-effective solution in a resource-limited setting, particularly in regions of the world where the incidence of MYCN-amplified NB is higher, such as in the Middle East. Furthermore, the potential influence of the patient’s genetic background on the phenotype of their tumors made us choose to investigate the correlation between the MYCN gene FISH results and IHC protein expression levels in two ethnically distinct groups of patients (MED and NAD). However, there was no statistically significant difference between them.

Although the overall correlation between a positive FISH assay and positive IHC testing was excellent (91.66%), the degree and level of intensity of the MYCN protein expression were diverse. Some cases with 100% of the analyzed cells by FISH with more than 10 copies of the gene displayed diffuse and strong immunoreactivity (Fig 1A), whereas others with a similar degree of gene amplification exhibited weaker or only focal nuclear positivity by IHC (Figs 1B-1D). This fact emphasizes the importance of IHC reaction optimization and interpretation. Careful analysis of the entire slide is critical. Nonetheless, previous studies have suggested that cases with MYCN gene amplification and diffuse and strong protein expression would correlate with a worse outcome when compared with cases with MYCN gene amplification but only focal positivity or negative MYCN IHC. Presently, only the MYCN gene status by FISH (not the protein expression level) is considered in the risk classification of patients with NB.

There was no statistical difference between patients of MED and NAD regarding the correlation between MYCN amplification status and MYCN protein expression level. Only three cases in our entire cohort of 78 (3.84%) demonstrated discordant results. One was an 11-year-old Lebanese boy who had a large retroperitoneal mass diagnosed as NB, Schwannian stroma-poor, poorly differentiated with low MKI but classified as unfavorable histopathology on the basis of INPC. FISH targeting the MYCN gene showed focal
amplification in 18.5% of the tumor cells analyzed. This patient was treated per the high-risk category and was alive with no evidence of disease at his last follow-up visit. MYCN IHC was performed twice in this case, and no evidence of MYCN protein expression was noted. It is possible that the tissue sections used for the IHC (although from the same paraffin block used for FISH) did not include the tumor component that harbors the amplification, or, even though the MYCN gene was amplified, the tumor cells, indeed, did not express the protein.

The other additional discordant results were two MYCN gene nonamplified cases that showed weak diffuse nuclear staining (IHC staining was repeated twice). One was the case of a 5-year-old Lebanese girl diagnosed with a stage 3 (abdominal mass) Schwannian stroma-poor, poorly differentiated, low-MKI NB (unfavorable INPC, high-risk category) who was alive at the last follow-up. The second case was that of a NAD female patient diagnosed with localized, thoracic, Schwannian stroma-poor, poorly differentiated, low-MKI NB (favorable INPC) who was alive and well at her follow-up. The association of undifferentiation or poorly differentiated morphology and high MKI with MYCN gene amplification in NB is well known. Interestingly, both cases had a low proliferative index and low MKI, which make us speculate that the weak IHC positivity could be due to very low levels of protein expression secondary to a mechanism other than gene amplification, or to just background staining. Nevertheless, it is our recommendation to reflex to FISH assay any case that demonstrates questionable or weak MYCN IHC staining.

When we examined our cohort on the basis of MKI (Fig 2), as expected, the highest percentage of MYCN-amplified cases were included in the high-MKI category (13 of 22; 59%) and no discrepancy between FISH and IHC results was observed in this subgroup. Only one of 12 (8.33%) intermediate-MKI case and two of 28 (7.14%) low-MKI cases had both MYCN gene amplification and MYCN protein expression. The low-MKI group, indeed, had the lowest incidence of MYCN gene amplification (7.14% low MKI v 59% high MKI; \(P < .01\)) and included all three discordant cases—the two previously discussed cases that had weak IHC staining but no gene amplification, and the one MYCN-amplified NB that lacked protein expression. Except for one case in which no viable residual tumor was available in the post-therapy resection specimen to perform MYCN IHC, all the remaining 15 cases (93.75%) in which MKI could not be assigned had concordant results (FISH positive/IHC positive, \(n = 7\); FISH negative/IHC negative, \(n = 8\)).

The FISH assay is considered the gold standard method of investigating MYCN gene status in patients with NB, but the upfront investment to implement a FISH laboratory versus introducing the IHC assay to an already-established anatomic pathology laboratory is considerably higher and, unfortunately, not feasible in many places. Whereas most laboratories now perform automated IHC, this assay, when well validated and applying stringent optimization, can be performed manually with good results. Considering the time, effort, complexity, and direct expenses, the final technical and interpretative cost of an individual FISH test or an IHC staining can vary from country to country, and
even within the same country, affected by local or regional factors. A comparison using the potential basic reimbursement offered by Medicare (or other third-party payers in the United States), based on the American Medical Association Current Procedural Terminology (CPT) coding, foresees a higher estimated fee for a FISH test compared with IHC: The cost of FISH, calculated as CPT 88271 times two probes plus CPT 88275 for interpretation of 100 to 300 cells plus CPT 88291 for reporting, is approximately $132.00; the cost of IHC, calculated as CPT 88342 technical component plus professional component, is approximately $65.00. All values are rounded up and expressed in US dollars without applying local modifiers or conversion factors. Although these estimated fees may not represent the actual cost of these tests, this analogy emphasizes that using IHC instead of the FISH could be a cost-effective solution for low- and middle income countries. In Lebanon, for instance, the price difference between a FISH assay and one IHC stain is also substantial (one FISH test costs approximately $300.00 vs one IHC, which costs approximately $100.00).

In summary, on the basis of the findings of this pilot analysis, we believe the use of MYCN IHC could be a good, cost-effective strategy to aid the diagnosis and classification of NB cases in areas where the implementation of FISH would be costly and technically challenging. Evaluation of a larger cohort of cases and, most importantly, optimization to perform MYCN IHC reaction manually, is still required.

**AFFILIATIONS**
1. St Jude Children’s Research Hospital, Memphis, TN
2. American University of Beirut Medical Center, Beirut, Lebanon

**CORRESPONDING AUTHOR**
Teresa Santiago, MD, Department of Pathology, St Jude Children’s Research Hospital, 262 Danny Thomas Pl, MS 250, Memphis, TN 38105-3678; e-mail: Teresa.Santiago@stjude.org.

**AUTHOR CONTRIBUTIONS**
Conception and design: Teresa Santiago, Sima Jeha, Carlos Rodriguez-Galindo
Provision of study material or patients: Teresa Santiago, Nidale Tarek
Collection and assembly of data: Teresa Santiago, Nidale Tarek, Fouad Boulos, Susana Raimondi, Carlos Rodriguez-Galindo
Data analysis and interpretation: Teresa Santiago, Caleb Hayes, Carlos Rodriguez-Galindo
Manuscript writing: All authors

**REFERENCES**
1. Cohn SL, Pearson AD, London WB, et al: The International Neuroblastoma Risk Group (INRG) classification system: An INRG Task Force report. J Clin Oncol 27:289-297, 2009
2. Henderson TO, Bhatia S, Pinto N, et al: Racial and ethnic disparities in risk and survival in children with neuroblastoma: A Children’s Oncology Group study. J Clin Oncol 29:76-82, 2011
3. Santiago T, Tarek N, Boulos F, et al: Rate of MYC-N-gene amplification among children of Middle Eastern descent with neuroblastoma. J Clin Oncol 36:e22507, 2018 (15_suppl)
4. Ward ZJ, Yeh JM, Bhakta N, et al: Estimating the total incidence of global childhood cancer: A simulation-based analysis. Lancet Oncol 20:483-493, 2019
5. Siegel DA, King J, Tai E, et al: Cancer incidence rates and trends among children and adolescents in the United States, 2001-2009. Pediatrics 134:e945-e965, 2014
6. Kamihara J, Ma C, Fuentes-Alabi SL, et al: Socioeconomic status and global variations in the incidence of neuroblastoma: Call for support of population-based cancer registries in low-middle-income countries. Pediatr Blood Cancer 64:321-323, 2017
7. Shapiro DN, Valentine MB, Rowe ST, et al: Detection of N-myc gene amplification by fluorescence in situ hybridization. Diagnostic utility for neuroblastoma. Am J Pathol 142:1339-1346, 1993
8. Shimada H, Stram DO, Chatten J, et al: Identification of subsets of neuroblastomas by combined histopathologic and N-myc analysis. J Natl Cancer Inst 87:1470-1476, 1995
9. Niemas-Teshiba R, Matsumo R, Wang LL, et al: MYC-family protein overexpression and prominent nucleolar formation represent prognostic indicators and potential therapeutic targets for aggressive high-MKI neuroblastomas: A report from the Children’s Oncology Group. Oncotarget 9:6416-6432, 2017
10. Wang LL, Teshiba R, Ikegaki N, et al: Augmented expression of MYC and/or MYCN protein defines highly aggressive MYC-driven neuroblastoma: A Children’s Oncology Group study. Br J Cancer 113:57-63, 2015
11. Chan HS, Gallie BL, DeBoer G, et al: MYCN protein expression as a predictor of neuroblastoma prognosis. Clin Cancer Res 3:1699-1706, 1997

**ACKNOWLEDGMENT**
We thank Laura Polk for her technical support.

**AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST**
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO’s conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jgo/site/misc/authors.html.

Carlos Rodriguez-Galindo
Honoraria: Novimmune
No other potential conflicts of interest were reported.

**FINAL MANUSCRIPT**
Final approval of manuscript: All authors
Accountable for all aspects of the work: All authors

**DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST**
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO’s conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jgo/site/misc/authors.html.

Carlos Rodriguez-Galindo
Honoraria: Novimmune
No other potential conflicts of interest were reported.

**ACKNOWLEDGMENT**
We thank Laura Polk for her technical support.